Survival and Treatment of Non-small Cell Lung Cancer Stage I–II Treated Surgically or with Stereotactic Body Radiotherapy: Patient and Tumor-Specific Factors Affect the Prognosis

Annals of Surgical Oncology

Volumn 22, Issue 1, 2015, Pages 316-323

  Mokhles, Sahar ^a   Nuyttens, Joost J ^b   Maat, Alex P W M ^a   Birim, Özcan ^a   Aerts, Joachim G J V ^a,c   Bogers, Ad J J C ^a   Takkenberg, Johanna J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

^c AMPHIA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADULT; AGED; CANCER STAGING; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW UP; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RADIOSURGERY; RETROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIOSURGERY; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84922460443     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3860-x     Document Type: Article

References (41)

1. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350(4):379–92.
2. Ferlay, J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765–81.
3. Ferlay, J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.
4. Howlader N, Noone AM, Krapcho M, et al.: SEER Cancer Statistics Review, 1975–2010, National Cancer Institute, Bethesda. http://seer.cancer.gov/csr/1975_2010/ (2013), based on November 2012 SEER data submission, posted to the SEER web site, April 2013.
5. Reck, M, Heigener DF, Mok T, et al. Management of non-small-cell lung cancer: recent developments. Lancet. 2013;382(9893):709–19.
6. van der Drift MA, Karim-Kos HE, Siesling S, et al. Progress in standard of care therapy and modest survival benefits in the treatment of non-small cell lung cancer patients in the Netherlands in the last 20 years. J Thorac Oncol. 2012;7(2):291–8.
7. Howlader N, Noone AM, Krapcho M, et al.: SEER Cancer Statistics Review, 1975–2010, National Cancer Institute, Bethesda. http://seer.cancer.gov/csr/1975_2010/ (2013), based on November 2012 SEER data submission, posted to the SEER web site, 2013.
8. Goldstraw P, Ball D, Jett JR, et al. Non-small-cell lung cancer. Lancet. 2011;378(9804):1727–40.
9. Vallieres E, Peters S, Van Houtte P, et al. Therapeutic advances in non-small cell lung cancer. Thorax. 2012;67(12):1097–101.
10. Crino L, Weder W, van Meerbeeck J, et al. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v103–15.
11. Guidelines Oncologic Care, Oncoline. Accessed 30 Oct 2013.Guidelines Oncologic Care, Oncoline. ccessed 30 Oct 2013.
12. van der Voort van Zyp NC, van der Holt B, van Klaveren RJ, et al. Stereotactic body radiotherapy using real-time tracking in octogenarians with non-small cell lung cancer. Lung Cancer. 2010;69(3):296–301.
13. Khakwani A, Rich AL, Powell HA, et al. Lung cancer survival in England: trends in non-small-cell lung cancer survival over the duration of the National Lung Cancer Audit. Br J Cancer. 2013;109(8):2058–65.
14. van der Pijl LL, Birim O, van Gameren M, et al. Validation of a prognostic model to predict survival after non-small-cell lung cancer surgery. Eur J Cardiothorac Surg. 2010;38(5):615–9.
15. Birim O, Kappetein AP, Waleboer M, et al. Long-term survival after non-small cell lung cancer surgery: development and validation of a prognostic model with a preoperative and postoperative mode. J Thorac Cardiovasc Surg. 2006;132(3):491–8.
16. Puri V, Crabtree TD, Kymes S, et al. A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in high-risk patients: a decision analysis. J Thorac Cardiovasc Surg. 2012;143(2):428–36.
17. Crabtree TD, Denlinger CE, Meyers BF, et al. Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2010;140(2):377–86.
18. Palma DA, Senan S. Improving outcomes for high-risk patients with early-stage non-small-cell lung cancer: insights from population-based data and the role of stereotactic ablative radiotherapy. Clin Lung Cancer. 2013;14(1):1–5.
19. Palma DA, Visser O, Lagerwaard FJ, et al. Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery. Radiother Oncol. 2011;101(2):240–4.
20. Goldstraw P. IASLC staging manual in thoracic oncology. 1st ed. Orange Park: Editorial Rx Press; 2009.
21. van der Voort van Zyp NC, Prevost JB, Hoogeman MS, et al. Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: clinical outcome. Radiother Oncol. 2009;91(3):296–300.
22. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.
23. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer. 2000;36(4):453–71.
24. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532–55.
25. Pellegrine R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948–68.
26. Donington J, Ferguson M, Mazzone P, et al. American College of Chest Physicians and Society of Thoracic Surgeons consensus statement for evaluation and management for high-risk patients with stage I non-small cell lung cancer. Chest. 2012;142(6):1620–35.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.
28. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29–36.
29. Lemeshow S, Hosmer DW Jr. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol. 1982;115(1):92–106.
30. Rubin DB. Multiple imputation for non-response in surveys. Wiley: New York; 1997.
31. Chansky K, Sculier JP, Crowley JJ, et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol. 2009;4(7):792–801.
32. Chi A, Liao Z, Nguyen NP, et al. Systematic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small cell lung cancer: clinical implications. Radiother Oncol. 2010;94(1):1–11.
33. Lagerwaard FJ, Verstegen NE, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;83(1):348–53.
34. Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys. 2011;81(5):1352–8.
35. Brundage MD, Davies D, Mackillop W. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002;122(3):1037–57.
36. Friedel G, Fritz P, Goletz S, et al. Postoperative survival of lung cancer patients: are there predictors beyond TNM? Anticancer Res. 2013;33(4):1609–19.
37. Stiles BM, Servais EL, Lee PC, et al. Point: clinical stage IA non-small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non-small cell lung cancer: the problem of understaging. J Thorac Cardiovasc Surg. 2009;137(1):13–9.
38. Lopez-Encuentra A, Farcia-Lujan R, Rivas JJ, et al. Comparison between clinical and pathologic staging in 2,994 cases of lung cancer. Ann Thorac Surg. 2005;79(3):974–9; discussion 979.
39. Chhatwani L. Cabebe E, Wakelee HA. Adjuvant treatment of resected lung cancer. Proc Am Thorac Soc. 2009;6:194–200.
40. Mannino DM, Aguayo SM, Petty TL, et al. Low lung function and incident lung cancer in the United States: data from the First National Health and Nutrition Examination Survey follow-up. Arch Intern Med. 2003;163(12):1475–80.
41. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.